350 related articles for article (PubMed ID: 11344179)
1. Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
Harris ST; Eriksen EF; Davidson M; Ettinger MP; Moffett AH; Baylink DJ; Crusan CE; Chines AA
J Clin Endocrinol Metab; 2001 May; 86(5):1890-7. PubMed ID: 11344179
[TBL] [Abstract][Full Text] [Related]
2. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
[TBL] [Abstract][Full Text] [Related]
3. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
4. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Wallach S; Cohen S; Reid DM; Hughes RA; Hosking DJ; Laan RF; Doherty SM; Maricic M; Rosen C; Brown J; Barton I; Chines AA
Calcif Tissue Int; 2000 Oct; 67(4):277-85. PubMed ID: 11000340
[TBL] [Abstract][Full Text] [Related]
5. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Fogelman I; Ribot C; Smith R; Ethgen D; Sod E; Reginster JY
J Clin Endocrinol Metab; 2000 May; 85(5):1895-900. PubMed ID: 10843171
[TBL] [Abstract][Full Text] [Related]
6. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
Wimalawansa SJ
Am J Med; 1998 Mar; 104(3):219-26. PubMed ID: 9552083
[TBL] [Abstract][Full Text] [Related]
7. Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Välimäki MJ; Farrerons-Minguella J; Halse J; Kröger H; Maroni M; Mulder H; Muñoz-Torres M; Sääf M; Snorre Øfjord E
Clin Ther; 2007 Sep; 29(9):1937-49. PubMed ID: 18035193
[TBL] [Abstract][Full Text] [Related]
8. Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.
Mortensen L; Charles P; Bekker PJ; Digennaro J; Johnston CC
J Clin Endocrinol Metab; 1998 Feb; 83(2):396-402. PubMed ID: 9467547
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
Delmas PD; Balena R; Confravreux E; Hardouin C; Hardy P; Bremond A
J Clin Oncol; 1997 Mar; 15(3):955-62. PubMed ID: 9060533
[TBL] [Abstract][Full Text] [Related]
10. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Reid DM; Adami S; Devogelaer JP; Chines AA
Calcif Tissue Int; 2001 Oct; 69(4):242-7. PubMed ID: 11730260
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
Palomba S; Orio F; Manguso F; Falbo A; Russo T; Tolino A; Tauchmanovà L; Colao A; Doldo P; Mastrantonio P; Zullo F
Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
[TBL] [Abstract][Full Text] [Related]
12. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
[TBL] [Abstract][Full Text] [Related]
13. Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
Dunn CJ; Goa KL
Drugs; 2001; 61(5):685-712. PubMed ID: 11368289
[TBL] [Abstract][Full Text] [Related]
14. Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Waldegger L; Zytaruk N; Shea B; Weaver B; Papaioannou A; Robinson V; Wells G; Tugwell P; Adachi JD; Guyatt G
Cochrane Database Syst Rev; 2003; (4):CD004523. PubMed ID: 14584020
[TBL] [Abstract][Full Text] [Related]
15. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
16. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
Bonnick S; Saag KG; Kiel DP; McClung M; Hochberg M; Burnett SM; Sebba A; Kagan R; Chen E; Thompson DE; de Papp AE
J Clin Endocrinol Metab; 2006 Jul; 91(7):2631-7. PubMed ID: 16636120
[TBL] [Abstract][Full Text] [Related]
17. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
[TBL] [Abstract][Full Text] [Related]
18. WITHDRAWN: Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Cranney A; Adachi JD; Guyatt G; Papaioannou A; Robinson VA; Shea BJ; Tugwell P; Waldegger LM; Weaver B; Wells G; Zytaruk N
Cochrane Database Syst Rev; 2007 Jul; (1):CD004523. PubMed ID: 17636764
[TBL] [Abstract][Full Text] [Related]
19. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Delmas PD; McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S
Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
